An interventional study of Ginkgo biloba capsule and Placebos in Primary Open Angle Glaucoma and Drug Effect, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Status unknown at 1 site in China. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-06.
Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment
Primary Open Angle Glaucoma (POAG) is an eye disease that causes optic nerve damage, visual field defect, and blindness caused by increased intraocular pressure. In recent years, many studies have shown that ginkgo biloba extract has a protective effect on the visual function of glaucoma patients. Studies have shown that Ginkgo biloba capsules can improve the visual field damage of glaucoma controlled by intraocular pressure;Ginkgo biloba capsule can promote the recovery of visual evoked potential of glaucoma controlled by intraocular pressure; the improvement of visual field has a certain correlation with visual electrophysiological recovery. The mechanism may be achieved by suppressing the influx of calcium ions and thereby inhibiting the apoptosis of cells. Therefore, in this clinical study, effect of Ginkgo biloba capsule on visual function of primary open-angle glaucoma with blood stasis syndrome was evaluated by placebo as control.
In this clinical study, the visual field, including MD, MS, LV, and vision score, are the main efficacy indicators. HRT and visual electrophysiological examination are the secondary efficacy indicators. Safety indicators based on laboratory tests and total frequency and incidence of adverse events. To evaluate the effectiveness and safety of Ginkgo biloba capsules for glaucoma patients with intraocular pressure control.
943 studies on the registry are indexed under Glaucoma, Open-Angle; 118 are open to participants now.
This study's planned enrollment of 512 is above the median of 80 across 710 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 164 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
Drug: Ginkgo biloba capsule
Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
Drug: Placebos
Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
Placebos were controls.
Mean defect of visual field (MD)
Detection by humphrey visual field meter
Time frame: After 48 weeks of treatment
Retinal nerve fiber layer thickness (RNFL)
Detection by optical coherence tomography (OCT)
Time frame: After 12, 24, 36, and 48 weeks of treatment
Plan to share: No — The archived documents and materials are not loaned. If the management department needs to access the original data, it should be agreed by the PI of the project.
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ginkgo biloba extract
Zhongshan Ophthalmic Center, Sun Yat-sen University →